Varaico: Literature-Extracted Genetic Variants

Gene:NRAS
Variant:p.A146T
Back to variants list

NRAS

NM_002524.5:p.A146T

Associated Papers

Next-Generation Sequencing-Based Detection of KRAS G12D Variants in Colorectal Cancer: A Retrospective Cohort Study.

Hekimoglu G et al.

Genes, 2026

Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.

Cheng WY et al.

Blood, 2025

40829168 (PubMed )
Supplement: BLOOD_BLD-2024-027692-mmc5.xlsx › Sheet_1

Tumor mutational burden modulates the prognostic effect of RAS mutations in metastatic colon cancer: mechanistic insights and genotype-phenotype correlations.

Ianniello M et al.

Journal of Translational Medicine, 2025

Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma.

Li Y et al.

British Journal of Haematology, 2025

40958529 (PubMed )
Supplement: supplement_1.zip › Table_S3.xlsx › Sheet1

Functional Analysis of Rare RAS Variants of Unknown Significance.

Park S et al.

Cancer Research Communications, 2025

40970755 (PubMed )
Supplement: crc-25-0188_supplementary_table_s5_suppst5.xlsx › Supplementary_Table_S5

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8-year study of 10 754 patients in Turkey.

Kavgaci G et al.

Molecular Oncology, 2025

Assessing mutation-clinical correlations and treatment outcomes in Vietnamese non-small cell lung cancer patients.

Nguyen HB et al.

Practical Laboratory Medicine, 2025

Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies.

Feichtenschlager V et al.

Communications Medicine, 2025

40473796 (PubMed )
Supplement: 43856_2025_932_MOESM3_ESM.xlsx › CRISPR

Subclonal TP53 and KRAS variants combined with poor treatment response identify ultrahigh-risk pediatric patients with T-ALL.

Kempter T et al.

Blood Advances, 2025

39808796 (PubMed )
Supplement: BLOODA_ADV-2024-014209-mmc1.pdf

The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma.

Berry D et al.

Cell Reports, 2025

Evolution of Neo-RAS-WT in Circulating Tumor DNA from First-Line to Subsequent Therapies in Metastatic Colorectal Cancer.

Siringo M et al.

Cancers, 2025

Molecular Mutations in Histiocytosis: A Comprehensive Survey of Genetic Alterations.

Pai P et al.

Molecular Biotechnology, 2025

Blastic plasmacytoid dendritic cell neoplasm secondary to acute myeloid leukemia with shared mutations in TET2 and DNMT3A: a case report and literature review.

Sun Y et al.

Frontiers in Immunology, 2025

Use of 3' Rapid Amplification of cDNA Ends (3' RACE)-Based Targeted RNA Sequencing for Profiling of Druggable Genetic Alterations in Urothelial Carcinomas.

Mitiushkina NV et al.

International Journal of Molecular Sciences, 2024

Genomic ascertainment to quantify prevalence and cancer risk in adults with pathogenic and likely pathogenic germline variants in RASopathy genes.

Kim J et al.

Medrxiv : the Preprint Server for Health Sciences, 2024

39802765 (PubMed )
Supplement: media-1.xlsx › Supplementary_Table_2

Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients.

Mosaferi Z et al.

Journal of Gastrointestinal Cancer, 2024

KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.

Mondal K et al.

Cells, 2024

Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients-Case Series and Literature Review.

Popescu I et al.

Journal of Personalized Medicine, 2024

39064004 (PubMed )
Supplement: jpm-14-00750-s001.zip › jpm-3006960-supplementary.pdf

Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy.

Osumi H et al.

Nature Communications, 2024

Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.

Douik H et al.

Anti-cancer Drugs, 2024

Identification and analysis of oncogenic non-synonymous single nucleotide polymorphisms in the human NRAS gene: An exclusive in silico study.

Mozibullah M et al.

Journal, Genetic Engineering & Biotechnology, 2024

38797553 (PubMed )
Supplement: mmc1.xlsx › Table_1

Clinical-Molecular characteristics and Post-Translational modifications of colorectal cancer in north China: Implications for future targeted therapies.

Chi Y et al.

Gene, 2024

RAS/RAF/MAPK Pathway Mutations as Predictive Biomarkers in Middle Eastern Colorectal Cancer: A Systematic Review.

Benmokhtar S et al.

Clinical Medicine Insights. Oncology, 2024

Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer.

Wu JB et al.

Biomedical Reports, 2023

Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis.

Imai M et al.

Esmo Gastrointestinal Oncology, 2023

41647731 (PubMed )
Supplement: mmc1.docx

A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer.

Osumi H et al.

Translational Oncology, 2023

Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania.

Afrăsânie VA et al.

International Journal of Molecular Sciences, 2023

Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease Progression.

Bang S et al.

Cancers, 2023

37568814 (PubMed )
Supplement: cancers-15-03998-s001.zip › Supplementary_Table_S3_Gene_Panel_Information.xlsx › Somatic_variants

RAS-targeted cancer therapy: Advances in drugging specific mutations.

Liu C et al.

Medcomm, 2023

Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.

Gao F et al.

Cancer Medicine, 2023

36971051 (PubMed )
Supplement: CAM4-12-10267-s001.xlsx › Sheet1

KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas.

Martianov AS et al.

International Journal of Molecular Sciences, 2023

KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer.

Shimozaki K et al.

Journal of Cancer Research and Clinical Oncology, 2023

Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial.

Schwab C et al.

Leukemia, 2023

36550215 (PubMed )
Supplement: 41375_2022_1799_MOESM1_ESM.pdf

Mutations in Classical Signaling Pathways and Their Functional Impact in Microsatellite Instability High Colorectal Cancer.

Shi S et al.

Genetic Testing and Molecular Biomarkers, 2023

Mapping the KRAS proteoform landscape in colorectal cancer identifies truncated KRAS4B that decreases MAPK signaling.

Adams LM et al.

The Journal of Biological Chemistry, 2023

36470426 (PubMed )
Supplement: mmc1.docx

Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer.

Sagawa T et al.

Frontiers in Oncology, 2023

Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory.

Bhai P et al.

Frontiers in Oncology, 2023

37483495 (PubMed )
Supplement: Table_1.xlsx › validation_II

Temporal genomic heterogeneity guiding individualized therapy in recurrent non-small cell lung cancer.

Fang Q et al.

Frontiers in Oncology, 2023

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.

Lee JK et al.

Npj Precision Oncology, 2022

36494601 (PubMed )
Supplement: 41698_2022_334_MOESM1_ESM.pdf

Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study.

Valladares-Ayerbes M et al.

Cancers, 2022

Rare presentation of multiple thromboses in Erdheim-Chester disease: a case-based review.

Liu Y et al.

International Journal of Hematology, 2022

Compartment-specific mutational landscape of clonal hematopoiesis.

Hartmann L et al.

Leukemia, 2022

36131041 (PubMed )
Supplement: 41375_2022_1700_MOESM1_ESM.pdf

[Laser microdissection for the analysis of molecular heterogeneity in colorectal cancer].

Maag N et al.

Pathologie (heidelberg, Germany), 2022

Delineating the RAS Conformational Landscape.

Parker MI et al.

Cancer Research, 2022

Performance of Idylla™ RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer.

Makutani Y et al.

International Journal of Clinical Oncology, 2022

1–50 of 178 papers
Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."